Pharmacologic neuroprotection: The search continues

Journal of Extra-Corporeal Technology

Volumn 39, Issue 4, 2007, Pages 296-301

  Grocott, Hilary P ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Brain; Cardiac surgery; Cardiopulmonary bypass; Neuroprotection; Pharmacology

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AL 208; APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMETHIAZOLE; DEXANABINOL; DEXTROMETHORPHAN; GANGLIOSIDE GM1; GLYPROMATE; KETAMINE; KTX 0101; LEXIPAFANT; LIDOCAINE; NEUROTROPHIC FACTOR; NIMODIPINE; PEGORGOTEIN; PEXELIZUMAB; PLACEBO; PROPOFOL; REMACEMIDE; STEROID; THIOPENTAL; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

BLEEDING; BRAIN BLOOD FLOW; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; NEUROLOGIC DISEASE; NEUROPROTECTION; RISK FACTOR; RISK REDUCTION; BRAIN ISCHEMIA; DRUG ANTAGONISM; REVIEW; THORAX SURGERY;

APROTININ; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CHLORMETHIAZOLE; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; THORACIC SURGERY;

EID: 40949119498     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Arrowsmith JE, Grocott HP, Newman MF. Neurologic risk assessment, monitoring and outcome in cardiac surgery. J Cardiothorac Vasc Anesth. 1999;13:736-43.
2. Dirnagl U, Iadecola C, Moskowitz M. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-7.
3. Nussmeier NA, Arlund C, Slogoff S. Neuropsychiatric complications after cardiopulmonary bypass: Cerebral protection by a barbiturate. Anesthesiology. 1986;64:165-70.
4. Michenfelder JD, Theye RA. Cerebral protection by thiopental during hypoxia. Anesthesiology. 1973;39:510-7.
5. Pascoe EA, Hudson RJ, Anderson BA, et al. High-dose thiopentone for open-chamber cardiac surgery: A retrospective review. Can J Anaesth. 1996;43:575-9.
6. Zaidan JR, Klochany A, Martin WM, Ziegler JS, Harless DM, Andrews RB. Effect of thiopental on neurologic outcome following coronary artery bypass grafting. Anesthesiology. 1991;74:406-11.
7. Warner DS, Takaoka S, Wu B, et al. Electroencephalographic burst suppression is not required to elicit maximal neuroprotection from pentobarbital in a rat model of focal cerebral ischemia. Anesthesiology. 1996;84:1475-84.
8. Zhou W, Fontenot HJ, Liu S, Kennedy RH. Modulation of cardiac calcium channels by propofol. Anesthesiology. 1997;86:670-5.
9. Pittman JE, Sheng H, Pearlstein R, Brinkhous A, Dexter F, Warner DS. Comparison of the effects of propofol and pentobarbital on neurologic outcome and cerebral infarct size after temporary focal ischemia in the rat. Anesthesiology. 1997;87:1139-44.
10. Young Y, Menon DK, Tisavipat N, Matta BF, Jones JG. Propofol neuroprotection in a rat model of ischaemia reperfusion injury. Eur J Anaesthesiol. 1997;14:320-6.
11. Wang J, Yang X, Camporesi CV, et al. Propofol reduces infarct size and striatal dopamine accumulation following transient middle cerebral artery occlusion: a microdialysis study. Eur J Pharmacol. 2002;452:303-8.
12. Roach GW, Newman MF, Murkin JM, et al. Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Anesthesiology. 1999;90:1255-64.
13. Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats. Neurosci Lett. 1997;228:45-9.
14. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 1998;804:169-76.
15. Kong RS, Butterworth J, Aveling W, et al. Clinical trial of the neuroprotectant clomethiazole in coronary artery bypass graft surgery: a randomized controlled trial. Anesthesiology. 2002;97:585-91.
16. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology. 1995;83:658-73.
17. MacGregor DG, Miller WJ, Stone TW. Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor. Br J Pharmacol. 1993;110:470-6.
18. Perez-Pinzon MA, Mumford PL, Rosenthal M, Sick TJ. Anoxic preconditioning in hippocampal slices: Role of adenosine. Neuroscience. 1996;75:687-94.
19. Grocott HP, Nussmeier NA. Neuroprotection in cardiac surgery. Anesthesiol Clin North America. 2003;21:487-509.
20. Levy JH, Ramsay J, Murkin J. Aprotinin reduces the incidence of strokes following cardiac surgery. Circulation. 1996;94:I-535.
21. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92:2236-44.
22. Frumento RJ, O'Malley CMN, Bennett-Guerrero E. Stroke after cardiac surgery: A retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg. 2003;75:479-83.
23. Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJ, O'Donnell AP, Shorten GD. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth. 2004;51:1002-9.
24. Murkin JM. Postoperative cognitive dysfunction: Aprotinin, bleeding and cognitive testing. Can J Anaesth. 2004;51:957-62.
25. Grocott HP, Sheng H, Miura Y, et al. The effects of aprotinin on outcome from cerebral ischemia in the rat. Anesth Analg. 1999;88:1-7.
26. Brooker RF, Brown WR, Moody DM, et al. Cardiotomy suction: A major source of brain lipid emboli during cardiopulmonary bypass. Ann Thorac Surg. 1998;65:1651-5.
27. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65.
28. Forsman M, Tubylewicz Olsnes B, Semb G, Steen P. Effects of nimodipine on cerebral blood flow and neuropsychological outcome after cardiac surgery. BJA. 1990;65:514-20.
29. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med. 1988;318:203-7.
30. Legault C, Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement. Report of an early terminated trial. Stroke. 1996;27:593-8.
31. Grieco G, d'Hollosy M, Culliford A, Jonas S. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of CMI ganglioside. Stroke. 1996;27:858-74.
32. Leon A, Lipartiti M, Seren MS, et al. Hypoxic-ischemic damage and the neuroprotective effects of GM1 ganglioside. Stroke. 1990;21:III95-7.
33. Arrowsmith JE, Harrison MJG, Newman SP, Stygall J, Timberlake N, Pugsley WB. Neuroprotection of the brain during cardiopulmonary bypass. A randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke. 1998;29:2357-62.
34. Ma D, Lynch J, Franks NP, Maze M, Grocott HP. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology. 2003;98:690-8.
35. Homi HM, Yokoo N, Ma D, et al. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology. 2003;99:876-81.
36. Homi HM, Yokoo N, Venkatakrishnan K, Bednar MM, Grocott HP. Neuroprotection by antagonism of the N-methyl-D-aspartate receptor NR2B subtype in a rat model of cardiopulmonary bypass. Anesthesiology. 2004;101:A878.
37. Schmitt B, Bauersfeld U, Fanconi S, et al. The effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan on perioperative brain injury in children undergoing cardiac surgery with cardiopulmonary bypass: Results of a pilot study. Neuropediatrics. 1997;28:191-7.
38. Nagels W, Demeyere R, Van Hemelrijck J, Vandenbussche E, Gijbels K, Vandermeersch E. Evaluation of the neuroprotective effects of s(+)-ketamine during open-heart surgery. Anesth Analg. 2004;98:1595-603.
39. Mitchell SJ, Pellett O, Gorman DF. Cerebral protection by lidocaine during cardiac operations. Ann Thorac Surg. 1999;67:1117-24.
40. Mathew JP, Grocott HP, Phillips-Bute B, Newman MF. Lidocaine does not prevent cognitive dysfunction after cardiac surgery. Anesth Analg. 2004;98:SCA13.
41. Amory DW, Grigore A, Amory JK, et al. Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: Evidence from 2,575 patients. J Cardiothorac Vasc Anesth. 2002;16:270-7.
42. Savitz SI, Erhardt JA, Anthony JV, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab. 2000;20:1197-204.
43. Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol. 1989;256:H589-93.
44. Butterworth J, Legault C, Stump DA, et al. A randomized, blinded trial of the antioxidant pegorgotein: No reduction in neuropsychological deficits, inotropic drug support, or myocardial ischemia after coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1999;13:690-4.
45. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-20.
46. Mathew JP, Shernan SK, White WD, et al. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke. 2004;35:2335-9.
47. Hofer RE, Christopherson TJ, Scheithauer BW, Milde JH, Lanier WL. The effect of a platelet activating factor antagonist (BN 52021) on neurologic outcome and histopathology in a canine model of complete cerebral ischemia. Anesthesiology. 1993;79:347-53.
48. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG. Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury. Biochem Biophys Res Commun. 1987;149:580-7.
49. Taggart D. Neuroprotection during cardiac surgery: a randomized trial of a platelet activating factor antagonist Fifth International Brain and Cardiac Surgery Conference, September 7-9, 2000. London, UK, 2000.
50. Clark RK, Lee EV, White RF, Jonak ZL, Feuerstein GZ, Barone FC. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res Bull. 1994;35:387-92.
51. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25:869-75.
52. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-11.
53. Chaney MA. Corticosteroids and cardiopulmonary bypass: A review of clinical investigations. Chest. 2002;121:921-31.
54. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet. 2004;364:1321-8.
55. Wass CT, Lanier WL. Glucose modulation of ischemic brain injury: Review and clinical recommendations. Mayo Clin Proc. 1996;71:801-12.
56. Li P, Kristian T, Shamloo M, Siesjo B. Effects of preischemic hyperglycemia on brain damage incurred by rats subjected to 2.5 or 5 minutes of forebrain ischemia. Stroke. 1996;27:1592-602.
57. Lam AM, Winn HR, Cullen BF, Sundling N. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg. 1991;75:545-51.
58. Puskas F, Grocott HP, White WD, Mathew JP, Newman MF, Bar-Yosef S. Hyperglycemia and increased incidence of cognitive deficit after cardiac surgery. Anesth Analg. 2005;100:SCA19.
59. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res. 2001;901:195-201.
60. Leker RR, Shohami E, Abramsky O, Ovadia H. Dexanabinol: A novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci. 1999;162:114-9.